[Pubmed] Selected clinical and demographic factors and all-cause mortality among individuals with Duchenne muscular dyst

[RSS-Bot]

Neuromuscul Disord. 2022 Apr 30:S0960-8966(22)00132-8. doi: 10.1016/j.nmd.2022.04.008. Online ahead of print.

ABSTRACT

Population-based estimates of survival among individuals with Duchenne muscular dystrophy (DMD) living in the United States are lacking. It is also unclear whether the association between glucocorticoid use and all-cause mortality persists in the context of other common treatments (cardiac medication, cough-assist, bilevel positive airway pressure, and scoliosis surgery) observed to delay mortality. Among 526 individuals identified by the Muscular Dystrophy Surveillance, Tracking, and Research Network, the estimated median survival time from birth was 23.7 years. Current glucocorticoid users had a lower hazard of mortality than non-users. Individuals who ever had scoliosis surgery had a lower hazard of mortality than individuals who did not have scoliosis surgery. Individuals who ever used cough assist had a lower hazard of mortality than individuals who never used cough assist. Non-Hispanic Black individuals had a higher hazard of mortality than non-Hispanic White individuals. No differences in hazards of mortality were observed between ever versus never use of cardiac medication and ever versus never use of bilevel positive airway pressure. The glucocorticoid observation is consistent with the 2018 Care Considerations statement that glucocorticoid use continues in the non-ambulatory phase. Our observations may inform the clinical care of individuals living with DMD.

PMID:35597713 | DOI:10.1016/j.nmd.2022.04.008


Source: https://pubmed.ncbi.nlm.nih.gov/3559771 ... 2&v=2.17.6